<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM23E21-5FV-FJ-WLJ"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 S2560 IS: Long COVID Support Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2023-07-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>118th CONGRESS</congress><session>1st Session</session><legis-num>S. 2560</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20230727">July 27, 2023</action-date><action-desc><sponsor name-id="S362">Mr. Kaine</sponsor> (for himself and <cosponsor name-id="S391">Mr. Young</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To address and support research on Long COVID.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Long COVID Support Act</short-title></quote>.</text></section><section id="id803f43dcbcff45fca9344a836c24c38f"><enum>2.</enum><header>Voluntary patient registry for research on Long COVID and related conditions</header><subsection id="id7659eb89f88941b2a9a3f68cde9616a8"><enum>(a)</enum><header>In general</header><text>The Secretary of Health and Human Services (referred to in this Act as the <quote>Secretary</quote>) shall carry out activities described in subsection (b) for treatment related to Long COVID and related conditions.</text></subsection><subsection id="id9dc67670a8de457ba0a6389fd729062e"><enum>(b)</enum><header>Activities described</header><text>For purposes of subsection (a), activities described in this subsection shall include—</text><paragraph id="id90d7811552eb47ffa5325915079189f9"><enum>(1)</enum><text>creating or maintaining a regularly updated voluntary patient registry of individuals with suspected or confirmed Long COVID and related conditions, including information on—</text><subparagraph id="idb56ebacb27124df1a6f1191551d7e849"><enum>(A)</enum><text>symptoms that arise while an individual is initially infected with COVID–19 and that may resolve over time or extend beyond the resolution of the initial symptoms;</text></subparagraph><subparagraph id="iddb1b9604ba2748cbbdad8c834d154528"><enum>(B)</enum><text>persistent symptoms that arise after an individual is initially infected with COVID–19 and that the clinician of such individual has reason to suspect were related to the COVID–19 diagnosis;</text></subparagraph><subparagraph id="id749f2358305e4f81a21debf34df6a89c"><enum>(C)</enum><text>symptoms that arise in an individual that may be related to COVID–19, but a diagnosis of COVID–19 was not obtained and cannot be identified due to a lack of antibodies, false negative test results, or lack of access to timely testing;</text></subparagraph><subparagraph id="idbaccd323dd5147b49c3433394ca4ff0d"><enum>(D)</enum><text>treatments of individuals after primary diagnosis of COVID–19 and the effectiveness of such treatments;</text></subparagraph><subparagraph id="id3a5de1710e264657be398135d78edfcb"><enum>(E)</enum><text>any other relevant questions or issues related to individuals who experience a diagnosis of, treatment for, and management of care with COVID–19, Long COVID, and related conditions; and</text></subparagraph><subparagraph id="idf7309750211d4856b317b8e45e2bf7ea"><enum>(F)</enum><text>comorbidities, vaccination status, and demographics, including age, gender, race and ethnicity, geographic location, and occupation of registry participants;</text></subparagraph></paragraph><paragraph id="idc76ad08dba814e25a287359f033af969"><enum>(2)</enum><text>information relating to individuals experiencing Long COVID and related conditions and other information available through the voluntary patient registry;</text></paragraph><paragraph id="idcbeee178acaf4c328451425b29ad9b9d"><enum>(3)</enum><text>dissemination of information to relevant Federal departments and agencies and patients participating in the voluntary patient registry related to COVID–19, Long COVID, and related conditions;</text></paragraph><paragraph id="id58045c4a74e740769d8730597c9dd1a7"><enum>(4)</enum><text>an assurance that the voluntary patient registry utilizes common data elements and definitions for use in order to promote appropriate data sharing for ongoing and future research; and</text></paragraph><paragraph id="id53765db5dfbf496a9ec853c1e8d43762"><enum>(5)</enum><text>outreach to, and inclusion in the voluntary patient registry, as appropriate, of individuals from communities impacted by high COVID–19 and Long COVID rates and health care providers from diverse disciplines that may treat individuals with COVID–19, Long COVID, and related conditions.</text></paragraph></subsection><subsection id="id710db00492da4c7ea42e8341829bb018"><enum>(c)</enum><header>Voluntary participation; privacy protections</header><paragraph id="id294c3bd00d894122ae304c5b689ae12e"><enum>(1)</enum><header>Voluntary participation</header><text>Participation in the patient registry described in subsection (b)(1) shall be voluntary, and a person creating, assisting in the creation of, or maintaining the registry shall not include in the registry information about an individual unless the individual consents to the inclusion of such information.</text></paragraph><paragraph id="id65e049895b014e4aa09c1f3ee47d7690"><enum>(2)</enum><header>Privacy protections</header><text>Information about an individual that is included in the registry shall be subject to all applicable privacy protections under Federal and State law.</text></paragraph></subsection><subsection id="idfc54f43b246a49c88d7b3651c371189c"><enum>(d)</enum><header>Report</header><text>Not later than 1 year after the establishment of the patient registry under subsection (b)(2), and annually thereafter, the Secretary shall submit a report that includes data, findings, and information with respect to the status of the patient registry (including progress, barriers, and issues) to Congress and the President.</text></subsection></section><section id="id494D5DBE82464E15B0F1EAF5D96A147A"><enum>3.</enum><header>Research and coordination of activities concerning the long-term health effects of Long COVID and related conditions</header><subsection id="id6effebb1657449538a60bbc57eb74b82"><enum>(a)</enum><header>In general</header><text>The Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall, as appropriate—</text><paragraph id="id05cc5c3c1c2246308684aed1d9b2aa2a"><enum>(1)</enum><text>coordinate activities among relevant Federal departments and agencies with respect to addressing the long-term health effects of Long COVID and related conditions, which may include conditions that arise as a result of such infection;</text></paragraph><paragraph id="id75baa5139982458f9d0c7ed3ae29c722"><enum>(2)</enum><text>continue to conduct or support basic, clinical, epidemiological, behavioral, and translational research and public health surveillance related to the pathogenesis, prevention, diagnosis, and treatment of the long-term health effects of Long COVID and related conditions, which may include conditions and any effects on development, cognition, and neural structure and function that arise as a result of such infection; and</text></paragraph><paragraph id="id39dc809a7c8d425f9f6bbaa3c061f9ea"><enum>(3)</enum><text>consistent with the findings of studies and research under paragraph (1), in consultation with health and public health professional associations, scientific and medical researchers, and other relevant experts, develop and inform recommendations, guidance, and educational materials on the long-term effects of Long COVID and related conditions, which may include conditions that arise as a result of such infection, and provide such recommendations, guidance, and educational materials to health care providers and the general public.</text></paragraph></subsection><subsection id="ida8d61ccd1f394fd9bfe65e067adef8a3"><enum>(b)</enum><header>Considerations</header><text>In conducting or supporting research under this section, the Secretary shall consider the diversity of research participants or cohorts to ensure inclusion of a broad range of participants, as applicable and appropriate.</text></subsection><subsection id="idc51849988daf4f8580da74112fc6f943"><enum>(c)</enum><header>Additional activities</header><text>The Secretary may—</text><paragraph id="id098379009e62466f973eeae0ba2699ca"><enum>(1)</enum><text>acting through the Director of the Agency for Healthcare Research and Quality, conduct or support research related to—</text><subparagraph id="idd890e30d23fb4abf8baac90193ed79ec"><enum>(A)</enum><text>the improvement of health care delivery for individuals experiencing long-term health effects of Long COVID and related conditions, which may include conditions that arise as a result of such infection; </text></subparagraph><subparagraph id="idd1dc626887e54bed8f4f9e665b44f76b"><enum>(B)</enum><text>the identification of any trends associated with differences in diagnosis and treatment of the long-term health effects of Long COVID and related conditions; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc5c7773517ea47b2b02c8f39a8e9b1e7"><enum>(C)</enum><text>the development or identification of tools and strategies to help health care entities and providers care for such populations, which may include addressing any differences identified pursuant to subparagraph (B); </text></subparagraph></paragraph><paragraph id="id77c9e554fc9e41bfbf99198de9baf551"><enum>(2)</enum><text>publicly disseminate the results of such research; and</text></paragraph><paragraph id="id7500a4c7b4b045eab63a9f0808c76b6f"><enum>(3)</enum><text>establish a primary care technical assistance initiative to convene primary care providers and organizations, which may include support for continuing training and education for such providers, as applicable and appropriate, in order to collect and disseminate best practices related to the care of individuals with long-term health effects of Long COVID and related conditions.</text></paragraph></subsection><subsection id="id3ee7f8dce51f4a20a3b9e8c5ef9695be"><enum>(d)</enum><header>Annual reports</header><text>Not later than 1 year after the date of enactment of this Act, and annually thereafter for the next 4 years, the Secretary shall prepare and submit a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives regarding an overview of the research conducted or supported under this section and any relevant findings. Such reports may include information about how the research and relevant findings under this section relate to other research efforts supported by other public or private entities.</text></subsection><subsection id="idd48ce62ab3014e4caf3b9e15631b1f74" commented="no" display-inline="no-display-inline"><enum>(e)</enum><header>Public availability of information</header><text>In making information or reports publicly available under this section, the Secretary shall take into consideration the delivery of such information in a manner that takes into account the range of communication needs of the intended recipients, including at-risk individuals.</text></subsection><subsection commented="no" display-inline="no-display-inline" id="id4ee2c8710a484a76b8088a768eae32bb"><enum>(f)</enum><header>Authorization of appropriations</header><text>To carry out subsection (c), there are authorized to be appropriated $10,000,000 for each of fiscal years 2024 through 2028.</text></subsection></section><section id="id38737f9d463244f7aad0522306f82878"><enum>4.</enum><header>Education and dissemination of information on Long COVID</header><subsection id="id4fb762d3438e4702bafa703642c19c66"><enum>(a)</enum><header>Long COVID public education program</header><text>The Secretary shall develop and disseminate to the public regularly updated information regarding Long COVID, in plain language, including information on—</text><paragraph id="id5f7ccfd1fc1e468c9fa23d12e6d8d826"><enum>(1)</enum><text>the awareness, incidence, and short- and long-term health effects associated with COVID–19 infection;</text></paragraph><paragraph id="id7a7ffb52df944e6f8a1bed628b66595f"><enum>(2)</enum><text>conditions related and often comorbid with Long COVID;</text></paragraph><paragraph id="iddf1610b37344420a8a1857332e5f2fca"><enum>(3)</enum><text>the availability, as medically appropriate, of treatment options for Long COVID and related conditions overlapping with Long COVID described in paragraph (2); and</text></paragraph><paragraph id="idaddbfbe0b2b44b66af7dd104fb668664"><enum>(4)</enum><text>strategies for reducing the likelihood of developing Long COVID.</text></paragraph></subsection><subsection id="idBC273471AE994968B547D9F91C1A2C2D"><enum>(b)</enum><header>Long COVID provider education program</header><text>The Secretary, in consultation with representatives from impacted communities and health care providers who treat such communities or individuals, shall develop and disseminate to health care providers, including by developing or improving continuing medical education programs that advance the education of such providers, information on Long COVID, recommended assessment tools, and management of Long COVID and related conditions for the purpose of ensuring that health care providers remain informed about current information on Long COVID and related conditions.</text></subsection><subsection id="id53bf207dd4e34b7b8229154a0f0e2774"><enum>(c)</enum><header>Considerations</header><text>In developing and disseminating information in subsections (a) and (b), the Secretary shall ensure that—</text><paragraph id="id0c85e83b63a14a10a2d3d42036047247"><enum>(1)</enum><text>guidance on Long COVID diagnostics, treatments, and care include demographic factors to address health disparities; and</text></paragraph><paragraph id="id7d1be0a6d1f94a98af8e724055bbb876"><enum>(2)</enum><text>individuals with Long COVID and related conditions, and entities representing such individuals, are empowered to participate in protocol development and outreach and education strategies.</text></paragraph></subsection><subsection id="id3fa6ba16c5b14ade8db0a4e22f880250"><enum>(d)</enum><header>Dissemination of information</header><text>The Secretary shall disseminate, in plain language, information under subsections (a) and (b), directly or through arrangements with intra-agency initiatives, nonprofit organizations, consumer groups, Federally qualified health centers, institutions of higher learning (as defined in section 101 of the Higher Education Act of 1965 (<external-xref legal-doc="usc" parsable-cite="usc/20/1001">20 U.S.C. 1001</external-xref>)), local educational agencies or State educational agencies (as defined in section 8101 of the Elementary and Secondary Education Act of 1965 (<external-xref legal-doc="usc" parsable-cite="usc/20/7801">20 U.S.C. 7801</external-xref>)), or Federal, State, Tribal, or local public private partnerships.</text></subsection></section><section id="id8697477696104217aedb415d1164eb02"><enum>5.</enum><header>Definition</header><text display-inline="no-display-inline">In this Act, the term <term>Long COVID</term> means health conditions that may result, directly or indirectly, from COVID–19. </text></section></legis-body></bill> 

